Infomed | International for Events

Best of ASCO Scientific Program: Friday, July 11 2008

Notice: All Abstracts were selected by ASCO, unless otherwise specified.

9:00 AM: Registration

10:00 AM Welcome and Introduction: Ali Shamseddine, MD/ Joseph Kattan, MD

10:15-11:00 AM: Highlights of the Days: Selected by: Ahmad Awada, MD, Ali Shamseddine, MD, Nagi Saghir, MD

11:00-12:30   Session I : Early Breast Cancer
                      Speakers: Ahmad Awada, MD, Nuhad Ibrahim, MD;
                                       Nagi Saghir, MD

Chairs: TBA:

· Muss, H. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older. Results of CALGB/CTSU 49907 (Presented by Nuhad Ibrahim, MD)

· Poole, C. tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early stage breast cancer (EBC) (Presented by Nuhad Ibrahim, MD)

· Goodman, P. Vitamin D (Vit D) deficiency is common at breast cancer (BC) diagnosis and is associated with a significantly higher risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC (Presented by Ahmad Awada, MD)

· Gnant, M. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. (Presented by Nagi Saghir, MD)

· Shapiro, C. Zoledronic Acid (ZA) preserves bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809 (Presented by Nagi Saghir, MD)

12:30pm -2:00pm LUNCH

2:00-3:00pm Session II: Breast Cancer – Metastatic Breast Cancer: 45 min
Speakers: Ahmad Awada, MD; Nuhad Ibrahim, MD

Chairs: TBA

· Miles, D. Randomised, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO (Presented by Ahmad Awada, MD)

· O’Shaughnessy, J. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy (Presented by Nuhad Ibrahim, MD)

· Carey, L. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal-like) breast cancer (Presented by Nuhad Ibrahim, MD)

· MacFarlane, R. Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population based database and tissue microarray series (Presented by Nuhad Ibrahim, MD)

· Management of Triple Negative Breast Cancer at MDAnderson Cancer Center. (Non-ASCO selection): uhad Ibrahim, MD

3:00-3:30pm Session III: Developmental Therapeutics: 45 minutes
Speakers: Ahmad Awada, MD

Chairs: TBA

· LoRusso, P. A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors (Presented by Ahmad Awada, MD)

· Atzori, F. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an Insulin Like Growth Factor-1 Receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors (Presented by Ahmad Awada, MD)

3:30-3;45pm Coffee Break

3:45-4;45pm: Session IV: Genitourinary Cancers: 1 hour
Speaker: Toni K, Choueiri, MD

Chairs: TBA

· Motzer, R. RAD001 plus best supportive care (BSC) vs BSC plus placebo in patients with metastatic renal cell carcinoma (RCC), which has progressed on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-3 study (Presented by Toni Choueiri, MD)

· Oliver, R. Radiotherapy versus Carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomised trial (ISRCTN27163214) (Presented by Toni Choueiri, MD)

· De Bono, J. Abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, has significant and durable anti-tumor activity in both chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC) (Presented by Toni Choueiri, MD)

· Alibahi, S. Impact of Androgen Deprivation Therapy (ADT) on bone, cardiovascular, and endocrine outcomes: a propensity-matched analysis of 20,000 patients (Presented by Toni Choueiri, MD)

· Management of Renal Cell Cancer at MGH (non-ASCO selection): Toni CHoueiri, MD)

4:45-5:15pm Session V: Gynecologic Cancer: 30 min
Speaker: Adnan Minkara, MD

Chairs: TBA

· Isonoshi, S. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology (Presented by Adnan Munkara, MD)

· Fong, P. AZD2281 (KU-0059436), a PARP (Poly ADP-ribose Polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a Phase I study ) (Presented by Adnan Munkara, MD)

5:15-5:45pm Session VI: Melanoma: 30 min
Speaker: Jaber Abbas, MD

Chairs: TBA

· McMasters, K. Final results of the Sunbelt Melanoma Trial) (Presented by Jaber Abbass, MD)

· Gimotty, P. Sentinel lymph node biopsy (SLNB) improves survival among SEER patients with melanoma (Presented by Jaber Abbass, MD

5:45-6:45pm Session VII: Patient and Survivor Care: 1 hour
Speakers: Fadlo Khuri, MD; Marwan Ghosn, MD; Sana Sukhun, MD

Chairs: TBA

· Vardy, J. Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer (Presented by Marwan Ghosn, MD)

· Mulrooney, D. Cardiovascular disease in adult survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study (CCSS) (Presented by Marwan Ghosn, MD)

· Kuhl, C. Management recommendations for women at increased familial risk for breast cancer: Results of a prospective national multi-modality cohort study (Presented by Sana Sukhun, MD)

· Morrow, G. A Phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP Study (Presented by Fadlo Khuri, MD)

· Limitations of the use of erythropoitin in the treatment of anemia in cancer patients (Non-ASCO selection): Fadlo Khuri, MS

9:00pm Gala Dinner

Scientific Program: Saturday July 12, 2008

10:00-11:00am Session VIII: Gastrointestinal (Colorectal) Cancer: 1 hour
Speakers: Ghassan Abou-Alfa, MD; Ali Shamseddine, MD

Chairs: TBA

· Ychou, M. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301) (Presented by Ali Shamseddine, MD)

· Punt, C. Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) (Presented by Ghassan Abou-Alfa, MD)

· Sargent, D. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials Presented by Ghassan Abou-Alfa, MD)

· Van Cutsem, E. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience Presented by Ghassan Abou-Alfa, MD)

· ImmunoHistochemistry and Molecular profiling in colorectal cancer (non-ASCO selection: Ghassan Abou-Alfa, MD

11:00- 12:15 PM Session IX: Gastrointestinal (Non-Colorectal) Cancer: 1 hour
Speakers: Ghassan Abou-Alfa, MD; Fady Geara, MD; Fadi Farhat, MD, Ali Shamseddine, MD

Chairs: TBA:

· Igaki, H. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907) Presented by Fadi Farhat, MD)

· Neuhaus, P. CONKO-001: Final Results of the randomized, prospective, multicenter phase 3 trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer (PC) Presented by Ali Samseddine, MD)

· Loehrer, P. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 Presented by Fady Geara, MD)

· Vervenne, W. A randomized, double blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer Presented by Ghassan Abou-Alfa, MD

· Cheng, A. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma Presented by Ghassan Abou-Alfa, MD)

· Management of metastatic hepatocellular carcinoma at Memorial Slaon kettering Cancer Center (Non-ASCO selection): Ghassan Abou-Alfa, MD

12:15-12:30 pm Coffee Break

12:30-1:15 pm Session X: Lymphoma: 45 min
Speakers: Hagop Kantarjian, MD, Ghazi Nsouli, MD

Chairs: TBA

· Gianni, A. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups: Presented byGhazi Nsouli, MD

· Czuczman, M. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma Presented by Hagop Kantarjian, MD

· Lenalidomide: Indications and usage at MDACC (Non-ASCO selection): Hagop Kantarijian

1:15 – 1:45pm Session XI: Myeloma: 30 min
Speakers: Fadi Nasr, MD, Ziad Salem

Chairs: TBA

· Barlogie, B. Total therapy (TT) for myeloma (MM): 10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2 Presented by Ziad Salem, MD

· Harousseau, I. Bortezomib/Dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial Presented by Fadi Nasr, MD

1:45- 3:00pm Lunch Break

3:00-4:00 pm Session XII: Leukemia: 1H
Speakers: Hagop Kantarjian, MD

Chairs: TBA

· Verstovsek, A. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF) Presented by Hagop Kantarjian, MD

· List, A. Azacitidine (AZA) extends overall survival in higher-risk myelodysplastic syndromes (MDS) without necessity for complete remission Presented by Hagop Kantarjian, MD

· Mauro, M. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) Presented by Hagop Kantarjian, MD

· New advances in the treatment of Acute Myeloid Leukemia (Non-ASCO selection): Hagop Kantarjian, MD

4:00—5:00 pm Session XIII: Lung Cancer – Non-Small Cell Carcinoma: 45 min
Speakers: Fadlo Khuri, MD, Georges Chahine, MD

Chairs: TBA

· Pirker, R. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC) (Presented by Georges Chahine, MD)

· Tsao, M. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients (Presented by Fadlo Khuri, MD)

· Ciuleanu, T. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study (Presented by Fadlo Khuri, MD)

· Management of metastatic NSCLC at Emory University (Non-ASCO selection): Fadlo Khuri, MD

5:00-6:00 pm Session XIV: Lung Cancer – Small Cell Carcinoma: 1 hour
Speakers: Fadlo Khuri, MD; Fady Geara, MD

` Chairs: TBA

· Natale, R. S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC) (Presented by Fadlo Khuri, MD)

· Heigener, D. Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): final results of a randomised phase III trial (Presented by Fadlo Khuri, MD)

· Socinski, M. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): Interim results (Presented by Fadlo Khuri, MD)

· Le Péchoux, C. Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): Primary end-point analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212): Presented by Fady Geara, MD

· Muss, H. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older. Results of CALGB/CTSU 49907 (Presented by Nuhad Ibrahim, MD)

· Poole, C. tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early stage breast cancer (EBC) (Presented by Nuhad Ibrahim, MD)

· Goodman, P. Vitamin D (Vit D) deficiency is common at breast cancer (BC) diagnosis and is associated with a significantly higher risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC (Presented by Ahmad Awada, MD)

· Gnant, M. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. (Presented by Nagi Saghir, MD)

· Shapiro, C. Zoledronic Acid (ZA) preserves bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809 (Presented by Nagi Saghir, MD)

· Miles, D. Randomised, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO (Presented by Ahmad Awada, MD)

· O’Shaughnessy, J. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy (Presented by Nuhad Ibrahim, MD)

· Carey, L. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal-like) breast cancer (Presented by Nuhad Ibrahim, MD)

· MacFarlane, R. Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population based database and tissue microarray series (Presented by Nuhad Ibrahim, MD)

· Management of Triple Negative Breast Cancer at MDAnderson Cancer Center. (Non-ASCO selection): uhad Ibrahim, MD

· LoRusso, P. A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors (Presented by Ahmad Awada, MD)

· Atzori, F. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an Insulin Like Growth Factor-1 Receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors (Presented by Ahmad Awada, MD)

· Motzer, R. RAD001 plus best supportive care (BSC) vs BSC plus placebo in patients with metastatic renal cell carcinoma (RCC), which has progressed on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-3 study (Presented by Toni Choueiri, MD)

· Oliver, R. Radiotherapy versus Carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomised trial (ISRCTN27163214) (Presented by Toni Choueiri, MD)

· De Bono, J. Abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, has significant and durable anti-tumor activity in both chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC) (Presented by Toni Choueiri, MD)

· Alibahi, S. Impact of Androgen Deprivation Therapy (ADT) on bone, cardiovascular, and endocrine outcomes: a propensity-matched analysis of 20,000 patients (Presented by Toni Choueiri, MD)

· Management of Renal Cell Cancer at MGH (non-ASCO selection): Toni CHoueiri, MD)

· Fong, P. AZD2281 (KU-0059436), a PARP (Poly ADP-ribose Polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a Phase I study ) (Presented by Adnan Munkara, MD)

· McMasters, K. Final results of the Sunbelt Melanoma Trial) (Presented by Jaber Abbass, MD)

· Gimotty, P. Sentinel lymph node biopsy (SLNB) improves survival among SEER patients with melanoma (Presented by Jaber Abbass, MD

· Vardy, J. Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer (Presented by Marwan Ghosn, MD)

· Mulrooney, D. Cardiovascular disease in adult survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study (CCSS) (Presented by Marwan Ghosn, MD)

· Kuhl, C. Management recommendations for women at increased familial risk for breast cancer: Results of a prospective national multi-modality cohort study (Presented by Sana Sukhun, MD)

· Morrow, G. A Phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP Study (Presented by Fadlo Khuri, MD)

· Limitations of the use of erythropoitin in the treatment of anemia in cancer patients (Non-ASCO selection): Fadlo Khuri, MS

Scientific Program: Saturday July 12, 2008

· Ychou, M. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301) (Presented by Ali Shamseddine, MD)

· Punt, C. Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) (Presented by Ghassan Abou-Alfa, MD)

· Sargent, D. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials Presented by Ghassan Abou-Alfa, MD)

· Van Cutsem, E. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience Presented by Ghassan Abou-Alfa, MD)

· ImmunoHistochemistry and Molecular profiling in colorectal cancer (non-ASCO selection: Ghassan Abou-Alfa, MD

· Igaki, H. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907) Presented by Fadi Farhat, MD)

· Neuhaus, P. CONKO-001: Final Results of the randomized, prospective, multicenter phase 3 trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer (PC) Presented by Ali Samseddine, MD)

· Loehrer, P. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 Presented by Fady Geara, MD)

· Vervenne, W. A randomized, double blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer Presented by Ghassan Abou-Alfa, MD

· Cheng, A. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma Presented by Ghassan Abou-Alfa, MD)

· Management of metastatic hepatocellular carcinoma at Memorial Slaon kettering Cancer Center (Non-ASCO selection): Ghassan Abou-Alfa, MD

· Gianni, A. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups: Presented byGhazi Nsouli, MD

· Czuczman, M. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma Presented by Hagop Kantarjian, MD

· Lenalidomide: Indications and usage at MDACC (Non-ASCO selection): Hagop Kantarijian

· Barlogie, B. Total therapy (TT) for myeloma (MM): 10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2 Presented by Ziad Salem, MD

· Harousseau, I. Bortezomib/Dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial Presented by Fadi Nasr, MD

· Verstovsek, A. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF) Presented by Hagop Kantarjian, MD

· List, A. Azacitidine (AZA) extends overall survival in higher-risk myelodysplastic syndromes (MDS) without necessity for complete remission Presented by Hagop Kantarjian, MD

· Mauro, M. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) Presented by Hagop Kantarjian, MD

· New advances in the treatment of Acute Myeloid Leukemia (Non-ASCO selection): Hagop Kantarjian, MD

· Pirker, R. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC) (Presented by Georges Chahine, MD)

· Tsao, M. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients (Presented by Fadlo Khuri, MD)

· Ciuleanu, T. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study (Presented by Fadlo Khuri, MD)

· Management of metastatic NSCLC at Emory University (Non-ASCO selection): Fadlo Khuri, MD

· Natale, R. S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC) (Presented by Fadlo Khuri, MD)

· Heigener, D. Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): final results of a randomised phase III trial (Presented by Fadlo Khuri, MD)

· Socinski, M. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): Interim results (Presented by Fadlo Khuri, MD)

· Le Péchoux, C. Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): Primary end-point analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212): Presented by Fady Geara, MD

5:00 PM Adjourn